Revised D&T Statement on GnRHa and Prolonged QT 2017

PES Drugs and Therapeutics Committee presents a statement on the Risk of Prolonged QT Interval with Gonadotropin Releasing Hormone Agonists.

Review of Prader-Willi Syndrome: The Endocrine Approach (Transl Pediatr. 2017)

A review of the current literature pertaining to the endocrine concerns of Prader Willi Syndrome and current recommendations for screening and management of these conditions.

Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline (JCEM 2017)

Monitoring Guidance for Patients with Hypophosphatasia Treated with Asfotase Alfa (Mol Genet Metab. 2017)

Clinical Practice Guidelines for the Care of Girls and Women with Turner Syndrome: Proceedings from the 2016 Cincinnati International TS Meeting (Eur J Endocrinol. 2017)

This paper is based on an international effort that started with exploratory meetings in 2014 in both Europe and the USA, and culminated with a Consensus…

Statement on Gender-Affirmative Approach to Care from the Pediatric Endocrine Society Special Interest Group on Transgender Health (Curr Opin, Peds 2017)

PES Statement Promoting Safety of Transgender Youth (PES Statement 2017)

Pediatric Obesity—Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline

National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Cardiovascular Disease and Associated Risk Factors Working Group Report

GH Deficiency, Idiopathic Short Stature, and IGF-I Deficiency Treatment Guidelines (HRP 2016)

PES Drugs and Therapeutics and Ethics committees present guidelines for Growth Hormone and Insulin-like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency.

Load More